Allergy/Imm Medical News about multiple sclerosis; interferon beta; earlier treatment

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta
Clinical Therapeutics, 08/20/09

Comi G – The evidence that axonal damage begins in the early stages of MS, before symptoms are evident, provides a rationale for early intervention with immunomodulatory agents. In 3 pivotal clinical trials, IFN–beta effectively reduced the risk of developing clinically definite MS in CIS patients with a first demyelinating event and positive brain MRI.

Methods

MEDLINE was searched (1990 – the end of 2008) for papers (human clinical trials in adults) published in English concerning the treatment of MS.

Results

Three pivotal randomized controlled trials were identified, 2 involving IFN–beta–1a (30 microg IM once weekly and 22 microg SC once weekly) and 1 involving IFN–beta–1b (250 microg SC qod).
In these trials, treatment with IFN–beta effectively reduced the risk of developing MS by up to 50% in patients with a CIS.
Compared with delayed treatment, early treatment was associated with a reduced risk of disease progression: a 40% reduction in risk for confirmed disability progression at 3 years and a 41% reduction in risk of MS at 3 years.

<< Previous
Levalbuterol versus albuterol

Next >>
Prevention of allergic sensitization by environmental control